May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

April 29, 2025

RadSearch Transforms Radiology Report Retrieval 

RadSearch could enhance radiologists' ability to find precedent cases.

Conexiant

April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant

April 24, 2025

Vitamin D Multifaceted CRC Immunomodulator Revealed

"Vitamin D enhances immune organ functions such as the spleen and lymph nodes, and boosts T-cell activity, which is essential in defending the body against tumors."

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 15, 2025

HPV Testing Guidelines Updated for Head and Neck Carcinomas

New evidence expands recommendations for sinonasal squamous cell carcinoma and standardizes p16 immunohistochemistry interpretation.

The Pathologist

February 12, 2025

FDA & EMA: Submitted Trial Data Discrepancies

Sample size discrepancies were identified in 13 trials (65%), with 8 differing by more than 10%.

Conexiant

November 07, 2024

AI in Neuropathology: How Language Models Are Transforming Brain Tumor Diagnosis

New research explores how integrating AI with clinical guidelines can enhance diagnostic precision for complex brain tumors.

Conexiant

September 26, 2024

T Cell Spatial Patterns Linked to CRC Survival

Study links shorter T-cell proximity to cancer cells with improved survival rates in colorectal cancer.

Conexiant